Tags

Type your tag names separated by a space and hit enter

[Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
Bull Cancer 2014; 101(9):881-90BC

Abstract

Nodular lymphocyte predominant Hodgkin disease (NLPHL) differs clearly from classical Hodgkin lymphoma (cHL) by clinical presentation and more favorable outcome. Patients often present with early stage IA or IIA. Extranodal disease and B-symptoms are uncommon. Histologically, NLPHL is characterized by the presence of atypical "lymphocyte predominant cells" (LP cells) or "pop-corn" cells in a non-neoplastic and reactionnal nodular background of small mature B-lymphocytes. LP cells are negative for CD30 and positive for CD20, BCL6 and EMA (in half of the cases). FDG-PET plays an important role in evaluation of cHL and NLPHL for staging, therapy assessment and relapse. Historically, patients with NLPHL have been treated like patients with cHL, but their very favorable prognosis and the risk of late complications of chemotherapy and/or radiotherapy have led to a de-escalation in recent years. Patients with early stage could be treated by surgical adenectomy alone or associated with not intensive chemotherapy. Currently, there is no consensus regarding to the optimal treatment of patients with advanced stage. Rituximab used as monotherapy or in association with chemotherapy has achieved complete or partial responses. The outcome of NLPHL is singular by the frequent occurrence of late relapses and the risk of transformation into aggressive B lymphoma justifying an extended follow-up. Further prospective studies are needed to optimize treatment of these advanced and recurrent forms.

Authors+Show Affiliations

CHU Reims, Hôpital Américain, Service d'hémato-oncologie pédiatrique, 47, rue Cognacq-Jay, 51100 Reims, France.CHU Reims, Hôpital Américain, Service d'hémato-oncologie pédiatrique, 47, rue Cognacq-Jay, 51100 Reims, France.CHRU Lille, Hôpital Jeanne de Flandre, Service d'hématologie pédiatrique, Lille, France.Hôpital d'enfants Armand Trousseau, Service d'anatomie et cytologie-pathologique, Paris, France.Hôpital Tenon, Service de médecine nucléaire, Paris, France.Hôpital d'enfants Armand Trousseau, Service d'hémato-oncologie pédiatrique, Paris, France.

Pub Type(s)

English Abstract
Journal Article
Review

Language

fre

PubMed ID

25296072

Citation

Gorde-Grosjean, Stéphanie, et al. "[Nodular Lymphocyte-predominant Hodgkin Lymphoma in Children: Clinical Course, Biology, and Management]." Bulletin Du Cancer, vol. 101, no. 9, 2014, pp. 881-90.
Gorde-Grosjean S, Guimard G, Lambilliotte A, et al. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management]. Bull Cancer. 2014;101(9):881-90.
Gorde-Grosjean, S., Guimard, G., Lambilliotte, A., Coulomb-Lhermine, A., Montravers, F., & Landman-Parker, J. (2014). [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management]. Bulletin Du Cancer, 101(9), pp. 881-90. doi:10.1684/bdc.2014.2021.
Gorde-Grosjean S, et al. [Nodular Lymphocyte-predominant Hodgkin Lymphoma in Children: Clinical Course, Biology, and Management]. Bull Cancer. 2014;101(9):881-90. PubMed PMID: 25296072.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management]. AU - Gorde-Grosjean,Stéphanie, AU - Guimard,Grégory, AU - Lambilliotte,Anne, AU - Coulomb-Lhermine,Aurore, AU - Montravers,Françoise, AU - Landman-Parker,Judith, PY - 2014/10/9/entrez PY - 2014/10/9/pubmed PY - 2015/4/2/medline KW - NLPHL KW - chemotherapy KW - nodular lymphocyte-predominant Hodgkin lymphoma KW - surgery SP - 881 EP - 90 JF - Bulletin du cancer JO - Bull Cancer VL - 101 IS - 9 N2 - Nodular lymphocyte predominant Hodgkin disease (NLPHL) differs clearly from classical Hodgkin lymphoma (cHL) by clinical presentation and more favorable outcome. Patients often present with early stage IA or IIA. Extranodal disease and B-symptoms are uncommon. Histologically, NLPHL is characterized by the presence of atypical "lymphocyte predominant cells" (LP cells) or "pop-corn" cells in a non-neoplastic and reactionnal nodular background of small mature B-lymphocytes. LP cells are negative for CD30 and positive for CD20, BCL6 and EMA (in half of the cases). FDG-PET plays an important role in evaluation of cHL and NLPHL for staging, therapy assessment and relapse. Historically, patients with NLPHL have been treated like patients with cHL, but their very favorable prognosis and the risk of late complications of chemotherapy and/or radiotherapy have led to a de-escalation in recent years. Patients with early stage could be treated by surgical adenectomy alone or associated with not intensive chemotherapy. Currently, there is no consensus regarding to the optimal treatment of patients with advanced stage. Rituximab used as monotherapy or in association with chemotherapy has achieved complete or partial responses. The outcome of NLPHL is singular by the frequent occurrence of late relapses and the risk of transformation into aggressive B lymphoma justifying an extended follow-up. Further prospective studies are needed to optimize treatment of these advanced and recurrent forms. SN - 1769-6917 UR - https://www.unboundmedicine.com/medline/citation/25296072/[Nodular_lymphocyte_predominant_Hodgkin_lymphoma_in_children:_clinical_course_biology_and_management]_ L2 - https://linkinghub.elsevier.com/retrieve/pii/bdc.2014.2021 DB - PRIME DP - Unbound Medicine ER -